Affibody’s partner Rallybio Announces Positive Phase 1 Results for RLYB116
• A single 100 mg subcutaneous dose demonstrated a reduction of >99% in free C5 and was generally well-tolerated. • Phase 1 Multiple Ascending Dose (MAD) study expected to commence in Q1, 2023. Solna, Sweden, November 7, 2022. Affibody’s licensee Rallybio Corporation (Nasdaq: RLYB), has announced positive topline results from a Phase 1 single ascending dose (SAD) study in healthy participants of RLYB116.In the ongoing Phase 1 study, all study participants that were administered a single 1 mL subcutaneous injection of 100 mg of RLYB116 (n=6) demonstrated a reduction in free C5 greater